🏛️ Verified NIH Record • Updated 2026-07-12
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis (NCT06097832)
Phase 1b/2 Study of NXC-201 for the Treatment of Patients With Relapsed or Refractory AL Amyloidosis
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Nexcella Inc.
🩺 Plain-English Summary (8th-Grade Level)
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
Who can join: Review the eligibility criteria below.
Location: Sutter Health Alta Bates — Berkeley, California
Age range: 18 Years to 120 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Sutter Health Alta Bates — Berkeley, California
- City of Hope — Duarte, California
- University of California Los Angeles — Los Angeles, California
- University of California Davis Medical Center — Sacramento, California
- Stanford University — Stanford, California
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- The University of Kansas Cancer Center — Fairway, Kansas
- Tufts Medical Center — Boston, Massachusetts
- Boston University Medical Center — Boston, Massachusetts
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- Masonic Cancer Center, University of Minnesota — Minneapolis, Minnesota
- Washington University Siteman Cancer Center — St Louis, Missouri
- Memorial Sloan Kettering Comprehensive Cancer Center — New York, New York
- University of Cincinnati Cancer Center — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Baptist Memorial Hospital — Memphis, Tennessee
- Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah
- Swedish Cancer Institute — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Light Chain (AL) Amyloidosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.